Diamyd kicks off recruitment campaign for Phase III in the US

Diamyd Medical AB (publ.) initiates the campaign for Phase III recruitment in the US, by exhibiting at the ADA conference in San Francisco 6th – 10th of June 2008.

ADA, American Diabetes Association 68th Scientific Sessions, is the world's largest exposition of diabetes-related products, services, and technology. More than 13,000 top scientists, physicians and other health care professionals from around the world will share cutting-edge research, treatment recommendations and advances toward a cure for diabetes.

”The ADA conference is an excellent opportunity for us to meet and talk to specialists in our field” says Elisabeth Lindner, President and CEO of Diamyd Medical. “We are focusing on information to specialists about the Phase III trials for the therapeutic diabetes vaccine Diamyd®, and we are also marketing Diamyd Medical and strengthening our brand as a committed diabetes company”.

Also attending the ADA conference is Professor Jerry Palmer, Lead Investigator for the Diamyd® Phase III trial in the US. Professor Palmer will chair a session called “Type 1 Diabetes Prevention”.